Neoadjuvant atezolizumab shows spatial biomarker changes in operable urothelial carcinoma patients.

This single-arm, phase II trial investigated the use of neoadjuvant atezolizumab in patients with operable urothelial carcinoma. The study population and specific sample size were not reported, and the setting was not specified. No comparator group was included in this design, and the primary outcome was not reported.

The analysis focused on secondary outcomes including clinical outcome, stable disease, relapse, immune activation, tissue remodeling, resistance pathways, transforming growth factor B (TGFB), spatial and phenotypic changes, carcinoma endothelial adjacency, and transcriptional programs. Cells residing in lymphoid aggregates and tertiary lymphoid structures (LAs/TLSs) were found to be more abundant in stable disease than in relapse. Gene expression programs were associated with improved survival in urothelial carcinoma. Additionally, carcinoma endothelial adjacency was reduced significantly following treatment and differed between groups. Spatial immune exclusion was associated with non-response despite immune expansion.

Safety and tolerability data, including adverse events, serious adverse events, discontinuations, and overall tolerability, were not reported. The follow-up duration was also not reported. Key limitations include the single-arm design, lack of a control group, and absence of reported safety data. The study was not funded or supported by entities with reported conflicts of interest.

These spatial and phenotypic biomarkers identified may inform rational combination strategies for immune checkpoint inhibitor refractory urothelial carcinoma. However, due to the study design and missing data, these findings should be interpreted with caution regarding immediate clinical practice.